Abstract
Tango Therapeutics Inc. will report fiscal results on March 5, 2026 Pre-Market; this preview summarizes last quarter’s performance and current-quarter expectations, including revenue, margins, net income, and adjusted EPS, and compiles the latest institutional perspectives within the January 1, 2026 to February 26, 2026 window.
Market Forecast
- For the current quarter, market and model inputs indicate revenue is projected at $0.50 million, implying a year-over-year decline of 93.56%; forecast EBIT is -$41.89 million with an implied year-over-year decline of 5.53%, and forecast adjusted EPS is -$0.32, with a year-over-year improvement of 5.55%. If margins are consistent with Tango Therapeutics Inc.’s revenue mix, gross margin may compress from the prior quarter’s partnership-driven peak and net margin may turn negative alongside the projected loss.
- The main business remains collaboration revenue; the outlook centers on timing of partner milestones and amortization of upfronts that can produce step-changes between quarters. The most promising contributor remains collaboration revenue, which delivered $53.81 million last quarter; year-over-year growth for that line was 363.61% given the large milestone recognition.
Last Quarter Review
- Tango Therapeutics Inc. reported the previous quarter with revenue of $53.81 million, a gross profit margin of 42.73%, GAAP net profit attributable to the parent company of $15.88 million, a net profit margin of 29.52%, and adjusted EPS of $0.14; revenue grew 363.61% year over year, while adjusted EPS rose 151.85% year over year.
- A notable highlight was the substantial collaboration milestone recognition that lifted revenue and turned EBIT and net income positive versus expectations. Main business highlights: collaboration revenue accounted for $53.81 million, underpinning the quarter’s growth surge and exceeding the earlier estimate of $37.14 million by 44.88%.
Current Quarter Outlook (with major analytical insights)
Main business: Collaboration revenue cadence and milestone timing
Collaboration revenue is expected to normalize significantly in the current quarter, with estimates pointing to $0.50 million. The step-down reflects limited milestone recognition and the absence of large catch-up amortization, highlighting the lumpiness inherent in development-stage partnerships. Given the 93.56% year-over-year decline implied by estimates, the quarter’s top line will likely be driven by base research support and modest amortization from upfronts. This revenue profile typically carries lower gross margin leverage, as fixed operating expenses—particularly R&D and G&A—dominate the cost base, and may pressure gross margin relative to the 42.73% reported previously. Investors should watch for commentary on upcoming clinical or preclinical milestones that could re-accelerate collaboration revenue in subsequent quarters.
Most promising business: Advancing partnered programs to unlock new milestones
The collaboration model concentrates growth potential in the progression of partnered programs toward key clinical readouts and development gates. As programs advance, contractual milestone payments can create episodic revenue inflections, while the base amortization provides a floor. The recent $53.81 million collaboration revenue underscores how single events can dominate a quarter’s financials and suggests that, even with a trough guide now, the medium-term path remains sensitive to pipeline catalysts. The company’s ability to move assets into new phases—and to expand partner scope—will be pivotal to restoring year-over-year growth after the current trough quarter.
Factors most likely to move the stock this quarter: Earnings mix, operating spend trajectory, and cash runway
With revenue guided to a trough-like level, investors will likely focus on operating discipline and cash runway. Forecast EBIT of -$41.89 million implies elevated operating spend consistent with pipeline execution; any signal of spend moderation or non-dilutive funding could cushion sentiment. Another swing factor is the magnitude of non-cash items affecting reported EPS; while EPS is forecast at -$0.32, small changes in fair-value or accrual timing can influence per-share outcomes. Lastly, qualitative guidance on the timing and likelihood of upcoming milestones can shift expectations for the back half of the year, as revenue is primarily milestone-driven.
Analyst Opinions
- Bullish views dominate recent commentary. One well-known institution reiterated a Buy rating with a price target of $18.00 on February 5, 2026, citing confidence in the partnership model and upcoming catalysts. Another maintained a Buy rating with a $13.00 target in October 2025, reflecting positive expectations for pipeline progression.
- The prevailing bullish stance emphasizes the asymmetric setup created by a trough revenue quarter followed by the potential for milestone-triggered upside. Analysts point to the prior quarter’s outperformance—actual revenue of $53.81 million versus an estimate of $37.14 million and positive EBIT of $14.07 million—as validation of the earnings volatility that can skew positively with pipeline progress. The majority argue that, while near-term revenue is likely to dip, visibility into partner-funded milestones, plus disciplined operating plans, supports a constructive outlook into the next catalyst windows. Investors are urged to monitor guidance on the cadence of collaboration milestones and any updates to program timelines, as these factors will most influence revisions and sentiment over the next two quarters.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments